Welcome to our dedicated page for Quantum BioPharma SEC filings (Ticker: QNTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quantum BioPharma Ltd. (QNTM) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer in the United States. Quantum BioPharma submits Form 6-K reports under the Securities Exchange Act of 1934, which include press releases, condensed consolidated interim financial statements, management’s discussion and analysis of financial condition and results of operations, material change reports, information circulars, and voting results. These documents give investors insight into the company’s biopharmaceutical activities in neurodegenerative and metabolic disorders and alcohol misuse disorders, as well as its capital markets and corporate actions.
Recent Form 6-K filings incorporate financial statements and MD&A for periods ended September 30, 2025, along with CEO and CFO certificates and related XBRL data. Other 6-Ks attach press releases covering topics such as clinical progress with Lucid-21-302 (Lucid-MS), at-the-market offering agreements, private placements, warrant expirations, and updates on the company’s digital asset portfolio. Additional filings include material change reports and management information circulars that document corporate decisions, shareholder meetings, and changes reported under Canadian securities rules but furnished to the SEC for U.S. investors.
Through these filings, users can review how Quantum BioPharma describes its lead MS program, licensing arrangements for unbuzzd , strategic investments via FSD Strategic Investments Inc., and litigation-linked contingent value rights (CVRs). The filings also reference the company’s registration statement on Form F-3, into which certain 6-K exhibits are incorporated by reference. On Stock Titan, these documents are updated from EDGAR in near real time and are accompanied by AI-powered summaries that highlight key points from each report, helping readers quickly understand financial disclosures, clinical milestones, capital structure changes, and other material information without reading every page.
Investors can use this filings page to locate Quantum BioPharma’s quarterly financial information, narrative analysis, press releases furnished as exhibits, and other regulatory documents that together outline the company’s operations, risk factors referenced in its Canadian and U.S. disclosures, and the evolution of its MS, alcohol health, and investment activities.
Quantum BioPharma reports that the U.S. FDA has placed the Investigational New Drug application for its multiple sclerosis candidate Lucid‑MS (Lucid‑21‑302) on clinical hold pending additional information. The company is reviewing the FDA’s comments and plans to submit a response package with its advisors and development partners.
Quantum is withdrawing previously disclosed timelines for FDA review, initiation of the planned Phase 2 trial, and interim data, which should no longer be relied upon. The company also announces that Dr. Lakshmi P. Kotra resigned as director and from all positions at Quantum and its subsidiaries, effective June 1, 2026, while remaining a senior clinical advisor.
Quantum BioPharma Ltd. has engaged IR Agency LLC, operating as Stocks.news, to provide investor relations, marketing, digital community building, news distribution and lead-generation services. The agreement begins on June 8, 2026, runs for six months and carries a fee of US$250,000.
The Agency is arm’s length to Quantum and neither it nor its principals hold, or have rights to acquire, any Quantum securities. The filing also reiterates Quantum’s business focus on therapies for neurodegenerative and metabolic disorders and alcohol misuse, and highlights its economic interest in Unbuzzd through both an equity stake and royalties.
Quantum BioPharma Ltd. reports reaching the halfway point in patient enrollment for its collaborative PET imaging study with Massachusetts General Hospital in multiple sclerosis. Early imaging data using the [ˆ⁸F]3F4AP tracer show strong signals in acute lesions and potential sensitivity to gray matter lesions.
The imaging approach aims to directly quantify demyelination and myelin repair, which could improve how therapies such as Quantum’s lead candidate Lucid-MS are evaluated. Lucid-MS targets PAD2 to prevent and reverse myelin degradation and has shown a favorable safety profile in prior Phase 1 trials, with an IND for a Phase 2 trial submitted in March 2026.
Quantum also highlights its economic interest in UNBUZZD, retaining 19.84% ownership as of March 31, 2026, plus a 7% royalty on sales until $250 million is paid, after which the royalty rate decreases to 3% in perpetuity.
Quantum BioPharma reported a much stronger liquidity position and key R&D progress for the first quarter of 2026. Combined cash, cash equivalents and digital assets were US$9.8 million as of March 31, 2026, more than double the US$4.1 million at year-end 2025, and management estimates this will fund operations to approximately July 2027.
Cash used in operating activities fell to US$1.66 million, a 60% year-over-year reduction, mainly from lower R&D spending after completing Phase 1 trials. The company filed an IND application with the FDA for its multiple sclerosis candidate Lucid-MS, signed a binding LOI with CRO Allucent for a planned Phase 2 trial, and appointed Dr. Salvatore Napoli as principal investigator. Quantum also highlighted Unbuzzd’s reorganization and new CEO to pursue an IPO, and noted that a U.S. court denied CIBC and RBC’s joint motion to dismiss Quantum’s lawsuit alleging stock market manipulation.
Quantum BioPharma Ltd. reports that its licensee, Unbuzzd Wellness Inc., has appointed Richard Buzbuzian as CEO to lead the nationwide commercialization of unbuzzd, a clinically validated beverage that accelerates alcohol metabolism and reduces hangover symptoms. The rollout is expected to start in South Florida and Texas and use multi-channel retail and e-commerce distribution.
Quantum BioPharma invented unbuzzd and, through its spin-out to Unbuzzd Wellness, retains 19.84% ownership as of December 31, 2025, plus a 7% sales royalty until payments reach $250 million, after which a 3% royalty continues in perpetuity. The release cites a peer-reviewed clinical study supporting unbuzzd’s efficacy and notes a functional beverage market projected to reach $198 billion in 2026 with a 10.79% CAGR, positioning the product within a large, growing category.
Quantum BioPharma Ltd. has submitted an Investigational New Drug (IND) application to the U.S. FDA for Lucid-21-302 (Lucid-MS), a first-in-class drug candidate for multiple sclerosis. The filing supports a planned Phase 2 clinical trial targeting demyelination, a core driver of MS progression.
The IND package includes nonclinical pharmacology, toxicology, manufacturing and quality data. Phase 1 trials of Lucid-MS were completed and described as safe and well-tolerated. Quantum outlines an expected timeline with FDA feedback and Phase 2 trial initiation targeted for Q2 2026 and interim Phase 2 data projected in Q4 2026.
The company highlights MS as a major global market, citing 2.8 million patients worldwide and a therapeutic market projected to exceed $38 billion by 2030. It also describes a diversified business model combining clinical development of Lucid-MS with consumer health revenues from UNBUZZD™ via a 7% royalty structure and retained economic rights.
Quantum BioPharma Ltd. has signed a binding Letter of Intent with global CRO Allucent to support a planned Phase 2 clinical trial of Lucid-21-302 (Lucid-MS) for multiple sclerosis. The company expects to initiate this Phase 2 study in the second quarter of 2026, subject to regulatory approvals and finalization of the clinical trial design and operations.
Lucid-MS is described as a first-in-class new chemical entity aimed at providing neuroprotection by inhibiting demyelination, a key driver of MS progression, offering a differentiated approach versus immune-modulating therapies. The release highlights an MS prevalence of about 2.8 million people worldwide and a therapeutic market projected to exceed $38 billion by 2030.
Quantum BioPharma also outlines its broader portfolio, including a 19.84% ownership (as of December 31, 2025) in Unbuzzd Wellness Inc., rights to royalties of 7% of unbuzzd™ sales until a total of $250 million is paid and 3% thereafter, and a tax loss carry forward of approximately C$130 million that could offset future taxable profits.